Last updated: 21 December 2020 at 4:40pm EST

Dirk Haasner Net Worth



Dirk Haasner biography

Dr. Dirk Haasner Ph.D. serves as Senior Vice President - Global Regulatory Affairs of the Company. Dr. Haasner previously served as our Vice President, Global Regulatory Affairs from December 2015 to March 2016. Prior to joining us, Dr. Haasner was Vice President Regulatory and Medical Affairs, and Vice President Regulatory Strategy and Policy at Lundbeck USA, Inc., a H. Lundbeck A/S subsidiary, from February 2002 to November 2015, with responsibility for all FDA interactions on several marketed orphan drugs and all Lundbeck development compounds. From 1994 to 2002, Dr. Haasner was employed at F. Hoffmann-La Roche AG, a publicly held healthcare company, where he held positions of increasing responsibility in global product development and global strategic marketing before being appointed Global Life-cycle Leader. Dr. Haasner co-founded the biotech start-up 4-Antibody AG that was acquired in 2014 by Agenus Inc., a publicly held biotechnology company. Dr. Haasner obtained a MSc in Molecular Biology at the University of Basel, Switzerland, a PhD in Cell Biology and Immunology at the Basel Institute for Immunology, and holds a postgraduate degree in Pharmaceutical Medicine from the EUCOR Universities Basel, Strasbourg and Freiburg.

What is the salary of Dirk Haasner?

As the Senior Vice President - Global Regulatory Affairs of Ovid Therapeutics Inc, the total compensation of Dirk Haasner at Ovid Therapeutics Inc is $1,178,980. There are 2 executives at Ovid Therapeutics Inc getting paid more, with Jeremy Levin having the highest compensation of $3,008,980.



How old is Dirk Haasner?

Dirk Haasner is 55, he's been the Senior Vice President - Global Regulatory Affairs of Ovid Therapeutics Inc since 2016. There are 9 older and 5 younger executives at Ovid Therapeutics Inc. The oldest executive at Ovid Therapeutics Inc is Bart Friedman, 75, who is the Lead Independent Director.

What's Dirk Haasner's mailing address?

Dirk's mailing address filed with the SEC is C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK, NY, 10036.

Insiders trading at Ovid Therapeutics Inc

Over the last 9 years, insiders at Ovid Therapeutics Inc have traded over $37,290 worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth $5,624,523 . The most active insiders traders include Pharmaceutical Co Ltdmillen..., Barbara Gayle Duncan a Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $229,440. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth $50,364.



What does Ovid Therapeutics Inc do?

ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/



What does Ovid Therapeutics Inc's logo look like?

Ovid Therapeutics Inc logo

Ovid Therapeutics Inc executives and stock owners

Ovid Therapeutics Inc executives and other stock owners filed with the SEC include: